MedPath

Nicorandil

Generic Name
Nicorandil
Drug Type
Small Molecule
Chemical Formula
C8H9N3O4
CAS Number
65141-46-0
Unique Ingredient Identifier
260456HAM0
Background

Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used for patients with angina who remain symptomatic despite optimal treatment with other antianginal drugs . Nicorandil is a dual-action potassium channel opener that relaxes vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and increased intracellular concentration of cyclic GMP. It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload .

Indication

Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.

Associated Conditions
Angina Pectoris

Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction

Phase 3
Conditions
Myocardial Infarction
Interventions
First Posted Date
2015-05-20
Last Posted Date
2017-09-20
Lead Sponsor
Pusan National University Hospital
Target Recruit Count
86
Registration Number
NCT02449070
Locations
🇰🇷

Pusan National University Hospital, Pusan, Korea, Republic of

Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction

Phase 4
Conditions
Coronary Heart Disease
Interventions
Drug: normal saline
First Posted Date
2015-05-06
Last Posted Date
2015-05-06
Lead Sponsor
Xuzhou Central Hospital
Target Recruit Count
100
Registration Number
NCT02435797
Locations
🇨🇳

Xuzhou Central Hospital, Xuzhou, Jiangsu, China

Efficacy Study of Nicorandil on Neointima

Phase 4
Conditions
Diabetes Mellitus
Angina, Unstable
Interventions
First Posted Date
2014-12-31
Last Posted Date
2015-01-21
Lead Sponsor
Zhang Ying Qian
Target Recruit Count
48
Registration Number
NCT02328521
Locations
🇨🇳

Chinese PLA General Hospital, Beijing, Beijing, China

Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow

Phase 4
Completed
Conditions
Slow Coronary Flow
Normal, or Near Normal Coronary Angiography
Stable Angina
Interventions
First Posted Date
2014-10-01
Last Posted Date
2015-03-31
Lead Sponsor
Mashhad University of Medical Sciences
Target Recruit Count
54
Registration Number
NCT02254252

Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil

Phase 4
Active, not recruiting
Conditions
Coronary Artery Disease
End Stage Renal Disease
Interventions
First Posted Date
2011-11-21
Last Posted Date
2024-03-07
Lead Sponsor
Kumamoto University
Target Recruit Count
268
Registration Number
NCT01475123
Locations
🇯🇵

Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.

Phase 4
Conditions
Chronic Stable Angina
Interventions
First Posted Date
2011-07-20
Last Posted Date
2011-12-08
Lead Sponsor
Ferozsons Laboratories Ltd.
Target Recruit Count
40
Registration Number
NCT01397994
Locations
🇵🇰

National Institute of Cardiovascular Diseases, Karachi, Sind, Pakistan

Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina

Phase 4
Completed
Conditions
Coronary Disease
Stable Angina
Interventions
Drug: Standard Treatment
First Posted Date
2011-07-18
Last Posted Date
2016-04-14
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Target Recruit Count
402
Registration Number
NCT01396395
Locations
🇨🇳

For Locations in, Beijing, China

A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization

Phase 4
Withdrawn
Conditions
Angina Pectoris
First Posted Date
2010-08-19
Last Posted Date
2014-07-02
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Registration Number
NCT01185015

Nicorandil Study to Reduce Cardiac Death After Percutaneous Coronary Intervention (PCI) in Hemodialysis Patients

Not Applicable
Completed
Conditions
Acute Myocardial Infarction
Congestive Heart Failure
Interventions
First Posted Date
2009-02-20
Last Posted Date
2009-02-20
Lead Sponsor
Toujinkai Hospital
Target Recruit Count
129
Registration Number
NCT00848562
Locations
🇯🇵

Toujinkai Hospital, Kyoto, Japan

Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris

Not Applicable
Terminated
Conditions
Microvascular Angina
Hypertension
Interventions
First Posted Date
2007-01-22
Last Posted Date
2009-05-06
Lead Sponsor
University of Aarhus
Target Recruit Count
10
Registration Number
NCT00424801
Locations
🇩🇰

Aarhus Hospital, Aarhus, Denmark

© Copyright 2025. All Rights Reserved by MedPath